Company Overview and News

 
Carotenoids Market to Witness Enhanced Application Scope in Food, Cosmetic and Pharmaceutical Sectors From 2014 to 2025: Million Insights

2017-10-03 prnewswire
The global carotenoids market was estimated at USD 1.21 billion in the year 2015 and is likely to witness significant growth, due to its increasing usage in numerous applications such as food, dietary supplements, animal feed, cosmetics and pharmaceuticals. Growing health awareness among consumers has led to increased usage of natural food products and nutritive supplements. This scenario is considered to drive the consumption of carotenoids over the years ahead.

 
Antioxidants: Applications and Global Markets

2017-09-25 prnewswire
LONDON, Sept. 25, 2017 /PRNewswire/ -- The global market for antioxidants should reach $6.4 billion by 2022 from $5.2 billion in 2017 at a compound annual growth rate (CAGR) of 4.2%, from 2017 to 2022. Download the full report: https://www.reportbuyer.com/product/2837391 • The rubber and latex application market for antioxidants is expected to grow from $2.2 billion in 2017 to nearly $2.7 billion in 2022 at a CAGR of 3.

 
Global Textural Food Ingredients Market: North America to Reach US$ 5,284.3 Mn by 2027- Future Market Insights

2017-09-13 prnewswire
APEJ to Witness Significant Growth in the Global Textural Food Ingredients Market During 2017 - 2027 | FMI

 
Natural Health Supplements Market to Reach US$ 68 Bn by 2024 - Persistence Market Research

2017-04-25 prnewswire
In various parts of the world, health supplements are included as a part of a diet that beholds higher nutritional value. The status of these health supplements also plays a key role in their sales. A majority of consumers will prefer that these nutritional ingredients get derived from natural or organic sources. Persistence Market Research's recently published study explores the global market for natural health supplements, projecting how the demand for natural health supplements will shape up in the years to come.

 
Delivra Strengthens Board for USA Product Launches

2016-04-18 marketwired
TORONTO, ON--(Marketwired - April 18, 2016) - Delivra Corp. (TSX VENTURE: DVA) ("Delivra" or the "Company") is pleased to announce the appointment of Mr. David T. Thibodeau to its Board of Directors.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...